The evidence on Zepbound weight loss at three months provides an early checkpoint. In a separate study of 135,349 people treated with semaglutide or tirzepatide, outcomes during the first year varied by brand: 10% to 34% lost more than 15% of their weight [2]. Across all four brands, 40% to 42% lost between 5% and 15%.
The brand comparison explains why treatment groups can differ even when they use the same active ingredient. Ozempic and Wegovy contain semaglutide, and Mounjaro and Zepbound contain tirzepatide. The products have different approved uses and dose schedules.
The guide to how long weight loss can take puts early changes in context. In a post hoc analysis of two tirzepatide trials, participants who had lost at least 5% at week eight lost more weight by week 72. Those below 5% at week eight also achieved clinically meaningful weight loss as a group [3].
A separate study tested seven machine learning models on existing patient records. For the strongest models, the area under the receiver operating characteristic curve was about 0.94 for weight loss and 0.79 for blood sugar control. Accuracy was about 89% to 90% for weight loss and 73% for blood sugar control [1].
The prediabetes screening analysis explains why a performance measure needs context. In this study, diabetes duration, baseline HbA1c and use of sulfonylureas or insulin were among the strongest predictors of blood sugar outcomes. The researchers tested the models using ten-fold cross-validation within their dataset [1].
There is also nothing here a buyer can act on. The predictors are baseline characteristics, so learning that your starting BMI predicts your response does not give you anything to change. The guide to why some people lose less weight on a GLP-1 explains how factors during treatment can affect the result.